Production (Stage)
ZYUS Life Sciences Corporation
ZYUS.V
TSX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -440.57% | 18.31% | -42.03% | 86.24% | -475.71% |
| Total Depreciation and Amortization | 7.04% | -0.51% | -0.65% | -10.72% | 5.72% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 6,438.01% | 38.26% | -5.71% | -98.92% | 13,096.94% |
| Change in Net Operating Assets | -301.23% | -58.45% | 1,568.01% | -118.31% | 124.99% |
| Cash from Operations | -245.42% | -238.62% | 83.46% | 3.27% | 68.47% |
| Capital Expenditure | 91.36% | -- | 100.00% | 82.14% | -440.61% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 16,618.52% | -- | 100.00% | 86.61% | -621.07% |
| Total Debt Issued | 1,566.67% | -25.00% | -- | -- | -- |
| Total Debt Repaid | 99.35% | -2,919.77% | 74.78% | -2.10% | 39.38% |
| Issuance of Common Stock | -100.00% | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 377.88% | 224.58% | 190.75% | -3.01% | 40.24% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 409.38% | -281.02% | 95.78% | 9.03% | 64.15% |